| abstract |
[Problem] To provide a novel therapeutic agent for diabetes which can be less apt to produce side effects such as persistent hypoglycemia.n[Solution] A compound characterized by containing a derivative of 1,1-diphenylsemicarbazide or 1,1-diphenylthiosemicarbazide as the active ingredient. Specifically, the compound is characterized by containing a derivative of either 1,1-diphenyl-4-cyclohexylsemicarbazide or 1,1-diphenyl-4-cyclohexylthiosemicarbazide as the active ingredient, and exhibits a hypoglycemic effect when orally administered. |